Loading resource…

Floraspe-Renzetti Hospital, ASL Lanciano-Vasto-Chieti; University of Pisa
The article provides an overview of the mechanisms by which factor XI inhibitors may prevent thrombosis while preserving hemostatic function. It discusses the current landscape of direct oral anticoagulants (DOACs) and introduces new agents targeting factor XI, which are being evaluated in clinical trials. The document emphasizes the importance of these inhibitors in specific patient populations, such as those undergoing major orthopedic surgery and cancer patients at high risk for venous thromboembolism.
No account needed